<DOC>
	<DOCNO>NCT00104897</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , 17-N-allylamino-17-demethoxygeldanamycin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well 17-N-allylamino-17-demethoxygeldanamycin work treat patient metastatic malignant melanoma .</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Treating Patients With Metastatic Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antitumor activity 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) patient metastatic malignant melanoma . - Determine progression-free rate patient treat drug . Secondary - Determine toxicity profile drug patient . - Determine duration response patient treated drug . - Determine survival patient treated drug . OUTLINE : This nonrandomized , open-label , multicenter study . Patients receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) IV 1 hour day 1 , 8 , 15 , 22 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . After 3 course treatment , disease response assess . Patients stable respond disease receive additional course treatment . After completion study treatment , patient follow 28 day every 3 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 15-25 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant melanoma Metastatic ( M1a , M1b , M1c ) disease Measurable disease clinical exam , xray , CT scan , MRI Must document disease progression 2 time point separate ≥ 6 month Preexisting visceral lesion appearance new visceral lesion allow New skin disease amenable surgery allow No primary brain tumor brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 9.0 g/dL Hepatic Bilirubin normal ALT AST ≤ 1.5 time upper limit normal No chronic liver disease No known hepatitis B C positivity Renal Creatinine &lt; 130 mmol/L OR Creatinine clearance &gt; 60 mL/min Cardiovascular No symptomatic congestive heart failure No myocardial infarction within past 6 month No unstable angina pectoris No cardiac arrhythmia No transient ischemic attack No stroke peripheral vascular disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week , , 6 month study participation No ongoing active infection No diabetes mellitus evidence severe peripheral vascular disease ulcers No history allergy egg No known HIV positivity No psychiatric illness social situation would preclude study compliance No uncontrolled illness No malignancy except adequately treat conebiopsied carcinoma situ cervix basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior immunotherapy Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy More 4 week since prior endocrine therapy Concurrent steroid allow provide give lowest possible maintenance dose Radiotherapy More 4 week since prior radiotherapy unless administer palliative care Concurrent radiotherapy allow provide administer single fraction bone pain OR indicate palliative care Surgery Not specify Other Recovered prior therapy Alopecia allow No concurrent therapeutic anticoagulation warfarin Concurrent prophylactic warfarin central line maintenance allow provide INR check regularly stable Concurrent lowmolecular weight heparin allow No concurrent anticancer therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>